{"entity":{"id":"da-lilly","kind":"company","name":"Eli Lilly","aka":[],"tldr":"Lilly developed donanemab and is running further amyloid-antibody studies.","summary":"Donanemab and remternetug sit on this company’s node so pipeline and approved products stay distinct.","asOf":"2026-09-21","links":[{"label":"Lilly","url":"https://www.lilly.com/"}],"tags":["dementia-atlas"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["da-donanemab","da-remternetug"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["da-trial-trailblazer-alz2","da-trial-expedition3"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Indianapolis","country":"US","companyType":"pharma","website":"https://www.lilly.com/","investors":[],"funding":[]},"route":"/companies/da-lilly/","neighbours":{"drug":[{"id":"da-donanemab","kind":"drug","name":"Donanemab","route":"/drugs/da-donanemab/"},{"id":"da-remternetug","kind":"drug","name":"Remternetug","route":"/drugs/da-remternetug/"}],"trial":[{"id":"da-trial-expedition3","kind":"trial","name":"EXPEDITION 3","route":"/trials/da-trial-expedition3/"},{"id":"da-trial-trailblazer-alz2","kind":"trial","name":"TRAILBLAZER-ALZ 2","route":"/trials/da-trial-trailblazer-alz2/"}],"cancer":[{"id":"alzheimers-disease","kind":"cancer","name":"Alzheimer’s disease","route":"/diagnoses/alzheimers-disease/"}]}}